PMID: 14662004

Zeitlin PL
Emerging drug treatments for cystic fibrosis.
Expert Opin Emerg Drugs. 2003 Nov;8(2):523-35., [PubMed]
Sentences
No. Mutations Sentence Comment
53 ABCC7 p.Pro574His
X
ABCC7 p.Pro574His 14662004:53:55
status: NEW
view ABCC7 p.Pro574His details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 14662004:53:45
status: NEW
view ABCC7 p.Asn1303Lys details
The ∆F508 mutation and others such as N1303K or P574H [26], which are also misprocessed in the ER, have been grouped together as Class 2 mutations in CFTR [27]. Login to comment
57 ABCC7 p.Trp1282*
X
ABCC7 p.Trp1282* 14662004:57:38
status: NEW
view ABCC7 p.Trp1282* details
ABCC7 p.Arg553*
X
ABCC7 p.Arg553* 14662004:57:46
status: NEW
view ABCC7 p.Arg553* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 14662004:57:31
status: NEW
view ABCC7 p.Gly542* details
Examples in this class include G542X, W1282X, R553X and 621 + 1 G→T. Login to comment
60 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 14662004:60:20
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Gly551Ser
X
ABCC7 p.Gly551Ser 14662004:60:30
status: NEW
view ABCC7 p.Gly551Ser details
This group includes G551D and G551S. Login to comment
61 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 14662004:61:78
status: NEW
view ABCC7 p.Gly551Asp details
A lead compound has already been identified that is capable of activating the G551D channel to near wild-type levels, offering the greatest hope for pharmacologic correction. Login to comment
63 ABCC7 p.Arg117His
X
ABCC7 p.Arg117His 14662004:63:0
status: NEW
view ABCC7 p.Arg117His details
ABCC7 p.Arg334Trp
X
ABCC7 p.Arg334Trp 14662004:63:7
status: NEW
view ABCC7 p.Arg334Trp details
ABCC7 p.Arg347Pro
X
ABCC7 p.Arg347Pro 14662004:63:17
status: NEW
view ABCC7 p.Arg347Pro details
R117H, R334W and R347P are examples of mutations that appear to yield a milder clinical phenotype even when in combination with a more severe allele. Login to comment
66 ABCC7 p.Ala455Glu
X
ABCC7 p.Ala455Glu 14662004:66:63
status: NEW
view ABCC7 p.Ala455Glu details
Examples of Class 5 mutations include 3849 + 10 kB C→T, A455E or 2789 + 5 G→A. Login to comment
88 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 14662004:88:313
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 14662004:88:616
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 14662004:88:636
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Arg117His
X
ABCC7 p.Arg117His 14662004:88:383
status: NEW
view ABCC7 p.Arg117His details
ABCC7 p.Pro574His
X
ABCC7 p.Pro574His 14662004:88:255
status: NEW
view ABCC7 p.Pro574His details
ABCC7 p.Ala455Glu
X
ABCC7 p.Ala455Glu 14662004:88:464
status: NEW
view ABCC7 p.Ala455Glu details
ABCC7 p.Trp1282*
X
ABCC7 p.Trp1282* 14662004:88:107
status: NEW
view ABCC7 p.Trp1282* details
ABCC7 p.Arg553*
X
ABCC7 p.Arg553* 14662004:88:122
status: NEW
view ABCC7 p.Arg553* details
ABCC7 p.Gly551Ser
X
ABCC7 p.Gly551Ser 14662004:88:320
status: NEW
view ABCC7 p.Gly551Ser details
ABCC7 p.Gly1349Asp
X
ABCC7 p.Gly1349Asp 14662004:88:327
status: NEW
view ABCC7 p.Gly1349Asp details
ABCC7 p.Ser1255Pro
X
ABCC7 p.Ser1255Pro 14662004:88:335
status: NEW
view ABCC7 p.Ser1255Pro details
ABCC7 p.Arg334Trp
X
ABCC7 p.Arg334Trp 14662004:88:390
status: NEW
view ABCC7 p.Arg334Trp details
ABCC7 p.Arg347Pro
X
ABCC7 p.Arg347Pro 14662004:88:397
status: NEW
view ABCC7 p.Arg347Pro details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 14662004:88:247
status: NEW
view ABCC7 p.Asn1303Lys details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 14662004:88:115
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Ser1455*
X
ABCC7 p.Ser1455* 14662004:88:531
status: NEW
view ABCC7 p.Ser1455* details
ABCC7 p.Gln1412Ser
X
ABCC7 p.Gln1412Ser 14662004:88:539
status: NEW
view ABCC7 p.Gln1412Ser details
Class of mutation Molecular mechanism Pancreatic status (if known) Examples 1 No CFTR protein synthesis PI W1282X, G542X, R553X, 621 + 1 G→T, 1717-1 G→A, 3905insT, 394delTT 2 Abnormal CFTR processing and trafficking PI ∆F508, N1303K, P574H 3 Defective CFTR regulation (normal trafficking) PI G551D, G551S, G1349D, S1255P 4 Decreased CFTR chloride conductance PS R117H, R334W, R347P, P547H 5 Reduced synthesis and trafficking of normal CFTR PS A455E, 3849 + 10kb C→T, (5T) 6A Reduced apical stability PI S1455X, Q1412S, 4326delTC, 4279insA 6B Defective regulation of other ion channels PI G551D Note that the G551D is placed in Class 3 for defective regulation and Class 6B for defective regulation of the outwardly rectifying chloride channel. Login to comment
91 ABCC7 p.Arg117His
X
ABCC7 p.Arg117His 14662004:91:23
status: NEW
view ABCC7 p.Arg117His details
When 5T is in cis with R117H, there is further reduction in CFTR function. Login to comment
117 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 14662004:117:128
status: NEW
view ABCC7 p.Gly551Asp details
Genistein, a tyrosine kinase inhibitor, not only stimulates ∆F508 chloride conductance, but is potent at stimulating the G551D mutant [66-70]. Login to comment
206 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 14662004:206:114
status: NEW
view ABCC7 p.Gly551Asp details
Fischer rat thyroid cells stably coexpressing the green fluorescent protein and either wild-type, ∆F508 or G551D CFTR were used to screen 60,000 chemically diverse compounds (at 10 µM) for activation of forskolin-mediated chloride efflux [144,145]. Login to comment
301 ABCC7 p.Pro574His
X
ABCC7 p.Pro574His 14662004:301:66
status: NEW
view ABCC7 p.Pro574His details
OSTEDGAARD LS, ZEIHER B, WELSH MJ: Processing of CFTR bearing the P574H mutation differs from wild-type and deltaF508-CFTR. Login to comment
416 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 14662004:416:129
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 14662004:416:130
status: NEW
view ABCC7 p.Gly551Asp details
69. ILLEK B, ZHANG L, LEWIS NC, MOSS RB, DONG JY, FISCHER H: Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am. J. Physiol. Login to comment